James Foster

Under his leadership, Charles River grew from a supplier of laboratory research models into the world's leading early-stage contract research organization (CRO), providing integrated drug discovery, safety assessment, and manufacturing support services to pharmaceutical and biotechnology companies globally. Foster's strategic vision transformed Charles River from a single-service provider into a "one-stop shop" for drug development. Through a series of acquisitions — including WIL Research, MPI Research, Citoxlab, and SAMDI Tech — he assembled a comprehensive portfolio spanning discovery services (target identification, lead optimization), safety assessment (GLP toxicology, ADME), and biologics testing and manufacturing support including cell and gene therapy CDMO capabilities. The company has faced headwinds in recent years as biotech funding tightened following the post-COVID boom, reducing demand for early-stage drug discovery services. Foster has navigated this downturn by focusing on cost management, capacity utilization, and longer-duration pharmaceutical customer relationships that provide more stable revenue. His decisions on capacity investment timing, acquisition strategy, pricing discipline in a softening market, and the balance between pharmaceutical and biotech customer exposure are the primary drivers of Charles River's stock.